|
| |
ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases
Entrepreneurial Company Award 2009
Appenzell, Switzerland, October 19, 2009 / b3c newswire / - ERGONEX Pharma
received one of the prestigious ‘European Orphan Diseases Entrepreneurial
Company Award’ on the occasion of Frost & Sullivan's '2009 Excellence in
Healthcare Awards Banquet,' held in London on 8th October 2009. The highly
competitive award was presented to ERGONEX Pharma in recognition of the
company's innovative therapeutic concept, its impressive display of
technological know-how and targeted vision.
ERGONEX Pharma is focused on the clinical development and commercialisation of
Terguride for the treatment of distinct orphan diseases. Terguride is currently
being evaluated for the treatment of pulmonary arterial hypertension (PAH) in a
Phase II trial in Europe and headline results are expected in 2010.
Dr. Rudolf Reiter, CEO of ERGONEX Pharma comments: "This award comes at an
exciting and challenging time for ERGONEX Pharma. I see it as recognition of the
vision, the commitment and work of the company, which would not have been
possible without the continued support, expertise and out-of-the-box thinking of
our partners in the on-going clinical trial. We believe that Terguride has the
potential to contribute a new quality to emerging combination therapies for
patients, who do not tolerate, have become resistant to or are insufficiently
controlled by current treatment options in PAH.”
The Frost & Sullivan Healthcare Awards Banquet honours Europe's best healthcare
companies for their achievements over the course of this year. Frost &
Sullivan's highly competitive awards recognise companies in a variety of
regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development.
About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disorder of the blood vessels in the
lung, in which the pressure in large blood vessel rises above normal. Walls of
the blood vessels are thickened and hardened, becoming less elastic. Hence, the
decrease in lumen leads to increases in pressure. Patients with PAH suffer from
extreme shortness of breath as the heart struggles to pump against these high
pressures causing such patients to ultimately die of heart failure.
About Terguride
Terguride acts as a potent antagonist on 5-HT2B and 5-HT2A receptors: It has
anti-proliferative and anti-fibrotic activities and drives reverse remodelling
processes. Serotonin is a signal molecule in the body with many functions. In
the blood vessel walls of the lung, it stimulates proliferation of smooth muscle
cells and narrowing of the blood vessels, which has been implicated in PAH.
Furthermore, trophic effects of serotonin on the heart contribute to right heart
hypertrophy and progression towards heart failure. Terguride is approved in
Japan for hyperprolactinemia acting as a partial dopamine agonist on the
pituitary gland.
About ERGONEX Pharma - www.ergonex.com
ERGONEX Pharma is a pharmaceutical company focused on developing and
commercialising well-tolerated and effective products for novel and typically
underserved indications. This is being achieved by forging collaborations with
commercial and academic partners with expertise in the field of interest and
through outsourcing activities to service providers.
Contact
ERGONEX Pharma GmbH
Ruetistr. 20
CH-9050 Appenzell
Switzerland
Phone: +41 71 788 4065
E-mail: info@ergonex.com
www.ergonex.com
| |
|
